Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: A real-world prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results